Description

Retatrutide 2 mg is the starting dose in most clinical research protocols for this next-generation triple hormone receptor agonist (targeting GLP-1, GIP, and glucagon receptors). As an investigational peptide, Retatrutide is being studied for its ability to support significant weight loss, improved insulin sensitivity, and metabolic health.

At the 2 mg strength, it is typically used in the early titration phase to allow the body to adjust and minimize side effects such as nausea. Higher doses (4 mg, 8 mg, and 12 mg weekly) are introduced gradually in ongoing Phase 3 clinical trials.